Tilray Brands, Inc. (TLRY)’s Potential Upside Meets a Cautious Consensus

Company Overview - Tilray Brands, Inc. (NASDAQ:TLRY) is a Canadian lifestyle consumer products company specializing in medical cannabis products, operating through four segments: Beverage, Cannabis, Distribution, and Wellness [4]. Analyst Sentiment - As of December 24, slightly more than 60% of analysts covering Tilray Brands assigned a Hold rating, while 36% recommended buying the stock [1]. - Bernstein analyst Nadine Sarwat reiterated a 'Market Perform' rating on December 22, significantly raising the price target from $1 to $10 [2]. Price Target and Potential - The target price for Tilray Brands ranges from $8.50 to $25, with a median price target of $19, indicating an upside potential of 88.49% [1]. Market Trends - Cannabis has emerged as a bipartisan issue, with 64% of Americans in favor of cannabis legalization by 2025, although this is a decrease from the 70% peak reported in 2023 [4]. - President Trump's cannabis-related Executive Order aims to reschedule cannabis from Schedule I to III and revise the statutory definition of hemp-derived cannabinoid products, which could accelerate research and establish a regulatory approach [3].